Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1284-5743 | Other Identifier | World Health Organization (WHO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
NNC0113-6856 is a new medicine which may help participants with type 2 diabetes to improve blood sugar control. NNC0113-6856 is slowly converted in the body to semaglutide, a substance similar to a hormone (signaling substance) in the body. The main purpose of this study will be to evaluate the safety of different strengths of NNC0113-6856 when given as multiple administrations, and the amount of NNC0113-6856 in the blood will be measured as well as the amount of specific parts (including semaglutide). Participants will either get multiple doses of the new medicine NNC0113-6856 or multiple doses of placebo (a "dummy" medicine that looks like the new medicine but is without any active ingredient). Whether participants get the new medicine or placebo is decided by chance. The duration of the study could last up to 25 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NNC0113-6856 | Experimental | Participants will receive NNC0113-6856 oral tablets. |
|
| Placebo | Experimental | Participants will receive NNC0113-6856 matching placebo oral tablets. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NNC0113-6856 | Drug | NNC0113-6856 will be administered as oral tablets. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Number of adverse events (AEs) | Measured as number of events. | From time of first dosing (day 1) until completion of the follow-up visit (day 148) |
| Measure | Description | Time Frame |
|---|---|---|
| Part 1 Multiple ascending dose (MAD): AUCτ,sema,SS: area under the semaglutide plasma concentration-time curve during a dosing interval τ at steady state | Measured in hours*nanomoles per liter (h*nmol/L). | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 1 (MAD): Cmax,sema,SS: maximum observed plasma concentration of semaglutide at steady state |
Not provided
Inclusion Criteria:
Additional for healthy Japanese participants:
Exclusion Criteria:
HbA1c greater than or equal to (≥) 6.5 percent (%) (48 millimoles per mole [mmol/mol]) at screening.
Any of the below laboratory safety parameters at screening outside the below laboratory range, see "Log of laboratory ranges used for laboratory parameter exclusion criterion" for specific values:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Transparency dept. 2834 | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Profil Institut für Stoffwechselforschung GmbH | Neuss | 41460 | Germany |
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
NNC0113-6856 matching placebo will be administered as oral tablets. |
|
Measured in nanomoles per liter(nmol/L). |
| From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 1 (MAD): AUCτ,6856,SS: area under the NNC0113-6856 plasma concentration-time curve during a dosing interval τ at steady state | Measured in h*nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 1 (MAD): Cmax,6856,SS: maximum observed plasma concentration of NNC0113-6856 at steady state | Measured in nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 1 (MAD): AUCτ,4768,SS: area under the NNC0113-4768 plasma concentration-time curve during a dosing interval τ at steady state | Measured in h*nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 1 (MAD): Cmax,4768,SS: maximum observed plasma concentration of NNC0113-4768 at steady state | Measured in nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 2 Dosing condition (DC): AUCτ,sema,SS: area under the semaglutide plasma concentration-time curve during a dosing interval τ at steady state | Measured in h*nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 50, 78 and 106 |
| Part 2 (DC): Cmax,sema,SS: maximum observed plasma concentration of semaglutide at steady state | Measured in nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 50, 78 and 106 |
| Part 2 (DC): AUCτ,6856,SS: area under the NNC0113-6856 plasma concentration-time curve during a dosing interval τ at steady state | Measured in h*nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 50, 78 and 106 |
| Part 2 (DC): Cmax,6856,SS: maximum observed plasma concentration of NNC0113-6856 at steady state | Measured in nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 50, 78 and 106 |
| Part 2 (DC): AUCτ,4768,SS: area under the NNC0113-4768 plasma concentration-time curve during a dosing interval τ at steady state | Measured in h*nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 50, 78 and 106 |
| Part 2 (DC): Cmax,4768,SS: maximum observed plasma concentration of NNC0113-4768 at steady state | Measured in nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 50, 78 and 106 |
| Part 3 Japanese (JP): AUCτ,sema,SS: area under the semaglutide plasma concentration-time curve during a dosing interval τ at steady state | Measured in h*nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 3 (JP): Cmax,sema,SS: maximum observed plasma concentration of semaglutide at steady state | Measured in nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 3 (JP): AUCτ,6856,SS: area under the NNC0113-6856 plasma concentration-time curve during a dosing interval τ at steady state | Measured in h*nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 3 (JP): Cmax,6856,SS: maximum observed plasma concentration of NNC0113-6856 at steady state | Measured in nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 3 (JP): AUCτ,4768,SS: area under the NNC0113-4768 plasma concentration-time curve during a dosing interval τ at steady state | Measured in h*nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |
| Part 3 (JP): Cmax,4768,SS: maximum observed plasma concentration of NNC0113-4768 at steady state | Measured in nmol/L. | From 0 to 168 hours after fourth dosing with the same dose at days 22, 50, 78 and 106 |